ReviewWorld journal of surgical oncology2014
Metabolic syndrome and renal cell carcinoma.
Review in World journal of surgical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 3 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Metabolic syndrome and increased susceptibility to renal cell carcinoma - a meta-analysis.BMC nephrology · 2025Pooled it
- Association Between Metabolic Syndrome and Risk of Renal Cell Cancer: A Meta-Analysis.Frontiers in oncology · 2022Pooled it
- The relationship between different dimensions of alcohol use and the burden of disease-an update.Addiction (Abingdon, England) · 2017Pooled it
- Article
- Metabolic reprogramming and immune microenvironment profiling in clear cell renal cell carcinoma: implications for prognosis, targeted therapy, and drug resistance.Discover oncology · 2025Article
- The association between the triglyceride-glucose index and prognosis in postoperative renal cell carcinoma patients: a retrospective cohort study.Frontiers in endocrinology · 2024Article
- Association of diabetes risk reduction diet with renal cancer risk in 101,755 participants: a prospective study.Journal of translational medicine · 2023Article
- System biology approaches identified novel biomarkers and their signaling pathways involved in renal cell carcinoma with different human diseases.Bioscience reports · 2022Article
- [Correlation between metabolic syndrome and prognosis of patients with clear cell renal cell carcinoma].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2022Article
- Renal Cell Cancer and Obesity.International journal of molecular sciences · 2022Review
- Association of metabolic syndrome and the risk of bladder cancer: A prospective cohort study.Frontiers in oncology · 2022Article
- Understanding the link between kidney stones and cancers of the upper urinary tract and bladder.American journal of clinical and experimental urology · 2022Review
- Could Metabolic Syndrome Be a Predictor of Survival Outcomes in Upper Tract Urothelial Carcinoma? A Propensity Score Matching Study in a Large Chinese Center.Frontiers in oncology · 2022Article
- Metabolic Syndrome is an Independent Risk Factor for Fuhrman Grade and TNM Stage of Renal Clear Cell Carcinoma.International journal of general medicine · 2022Article
- Effects of metabolic syndrome on renal function after radical nephrectomy in patients with renal cell carcinoma.International urology and nephrology · 2021Article
- The Role of Metabolic Factors in Renal Cancers.International journal of molecular sciences · 2020Review
- Influence of Hypertension on the Survival of Non-Small Cell Lung Cancer Patients with Type 2 Diabetes Mellitus.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Oncometabolites in renal cancer.Nature reviews. Nephrology · 2020Review
- MCP-1/MCPIP-1 Signaling Modulates the Effects of IL-1β in Renal Cell Carcinoma through ER Stress-Mediated Apoptosis.International journal of molecular sciences · 2019Article
- Metabolic syndrome is associated with improved cancer-specific survival in patients with localized clear cell renal cell carcinoma.Translational andrology and urology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic syndrome (MS) is a cluster of metabolic abnormalities, which has been regarded as a pivotal risk factor for cardiovascular diseases. Recent studies focusing on the relationship between MS and cancer have recognized the significant role of MS on carcinogenesis. Likewise, growing evidence suggests that MS has a strong association with increased renal cell carcinoma (RCC) risk. This review outlines the link between MS and RCC, and some underlying mechanisms responsible for MS-associated RCC. MATERIALS AND
methodsA National Center for Biotechnology Information PubMed search (http://www.pubmed.gov) was conducted using medical subject headings 'metabolic syndrome', 'obesity', 'hypertension', 'diabetes', 'dyslipidemia', and 'renal cell carcinoma'.
resultsThis revealed that a variety of molecular mechanisms secondary to MS are involved in RCC formation, progression, and metastasis. A deeper understanding of these molecular mechanisms may provide some strategies for the prevention and treatment of RCC.
conclusionsIn summary, there is a large body of evidence regarding the link between MS and RCC, within which each component of MS is considered to have a close causal association with RCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.